 | • レポートコード：D0-MOR-AP1211 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、ワルファリン感受性試験の世界市場について調査・分析した資料で、ワルファリン感受性試験の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The warfarin sensitivity test market is expected to register a healthy CAGR during the forecast period. The major contributing factors responsible for driving the market growth are the increasing burden of blood-related disorders and technological advancements in the field. Thrombosis refers to the condition wherein a clot is formed in a blood vessel. According to the International Society of Thrombosis and Haemostasis, around 1 out of 4 people die due to thrombosis globally each year. Furthermore, according to the Centre for Disease Control and Prevention, in 2020, between 60,000 to 100,000 people died due to thrombosis in the United States and approximately 5 % to 8 % of the population have a genetic defect. The treatment for these disorders involves warfarin drug and hence, the warfarin sensitivity test market is expected to witness high growth over the forecast period.
Key Market Trends
Genetic Testing Segment is Expected to Hold a Major Market Share in the Warfarin Sensitivity Test Market
– Warfarin is the most widely used anticoagulant for the treatment of thrombosis. However, the sensitivity towards it can cause serious complications such as heart stroke, peptic diseases, uncontrolled blood pressure, etc. The sensitivity depends upon the number of copies of the altered gene in the cell. According to the study published by BMC Medicine, in 2019, the accurate dose of warfarin was determined in the patients with the help of a point-of-care genotyping information approach.
– In addition, according to the data published by the International Society on Thrombosis and Haemostasis, Inc. every year the United States experiences an approximate of 100,000 to 300,000 deaths related to venous thromboembolism, while in Europe it is observed to be approximately 554,000 deaths.
– Furthermore, according to the National Institute of Health, approximately 2 million people have prescribed warfarin annually and around 35,000 to 45,000 people visit the hospital for adverse events due to warfarin. Therefore, the aforementioned factors are expected to fuel the market growth in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the global warfarin sensitivity test market due to the rise in the aging population and the associated bleeding disorders. The geriatric population is at a higher risk of warfarin sensitivity. The elder population has decreased metabolic activities which alter the pharmacokinetics of the drug and thereby higher sensitivity is observed in the geriatric population. According to the data published by the U.S. Census Bureau in 2018, there were around 52 million populations living at the age of 65 and above. Furthermore, according to the Centre for Disease Control and Prevention, atleast 900,000 people are likely to be suffered from venous thromboembolism. Hence, these factors are expected to propel the warfarin sensitivity test market growth.
Competitive Landscape
Companies are constantly focused on developing new products related to warfarin sensitivity test to grow their presence in the market. For instance, in 2019, Eurolyser DIagnostica Gmbh added bidirectional connectivity to the “CUBE” series to enhance the data management software. Some of the companies which are currently dominating the market are AutoGenomics, Abbott, Eurolyser Diagnostica GmbH, TrimGen Corporation, Generi Biotech, F. Hoffmann-La Roche Ltd., Acon Laboratories, Inc. and Coagu Sense Inc.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Blood Related Disorders
4.2.2 Rising Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Instrument
5.1.2 Consumable
5.2 By Test Type
5.2.1 Genetic
5.2.2 Non-genetic
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Acon Laboratories, Inc.
6.1.3 AutoGenomics
6.1.4 Coagu Sense Inc.
6.1.5 Eurolyser Diagnostica GmbH
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Generi Biotech
6.1.8 TrimGen Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS